Group 1: Company Overview and Leadership - Beida Pharmaceutical Co., Ltd. held an investor communication meeting on October 27, 2018, in Beijing, attended by key executives including CEO Dr. Ding Li Ming and several senior vice presidents [1][2]. - The company focuses on market sales, strategic cooperation, and new drug development, emphasizing open communication with investors [2][3]. Group 2: Research and Development Strategy - Beida has a high R&D investment ratio, which has impacted performance; however, it has built a rich R&D pipeline with over 30 projects under development, 8 of which are in clinical research [3][4]. - The company’s R&D strategy is guided by market demand and scientific innovation, focusing on oncology with a balanced approach to small molecule targeted drugs, immunotherapy, and combination therapies [3][4]. Group 3: Product Performance and Market Impact - The drug Camrelizumab (凯美纳) has benefited over 180,000 late-stage lung cancer patients, with cumulative sales nearing 5.5 billion yuan; its sales increased by 30.38% year-on-year in Q3 2018 [4][5]. - Camrelizumab's inclusion in the National Essential Medicines List is expected to enhance its market accessibility, with a significant patient population still needing effective treatments [4][5]. Group 4: Financial Performance - In Q3 2018, the company reported a net profit of 81.09 million yuan, a year-on-year increase of 22.22%, alongside a revenue growth of 28.18% [4][5]. - The company is actively managing shareholder equity pledges and financing, ensuring compliance with regulatory requirements while addressing market pressures [6][7]. Group 5: Talent Management and Organizational Development - Beida currently employs nearly 1,200 staff, up from under 1,000 at the end of 2017, reflecting a strategic focus on talent acquisition and retention [6][7]. - The company has established a supportive work environment and incentive systems, including milestone bonuses and equity incentives, to foster employee engagement and stability [6][7].

Financial Performance - Total revenue for Q3 2022 was ¥409,380,718.51, a decrease of 28.09% year-over-year[5] - Net profit attributable to shareholders was ¥8,089,152.51, down 93.86% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥2,605,039.63, a decline of 97.98% year-over-year[5] - Total operating revenue for Q3 2022 was CNY 1,662,717,674.70, a decrease of 3.58% compared to CNY 1,724,419,673.98 in the same period last year[22] - The net profit for the third quarter of 2022 was approximately ¥88.79 million, a decrease of 74.1% compared to ¥342.69 million in the same period last year[23] - Operating profit for the quarter was ¥93.99 million, down 75.5% from ¥383.48 million in the previous year[23] - Total comprehensive income for the quarter was ¥139.73 million, down 66.7% from ¥419.24 million year-on-year[23] - The basic earnings per share for the quarter was ¥0.25, compared to ¥0.84 in the same period last year[23] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥209,680,381.29, a decrease of 54.46% compared to the previous year[9] - Cash flow from operating activities generated a net amount of ¥209.68 million, a decline of 54.5% compared to ¥460.46 million in the same period last year[24] - The company reported a decrease in cash and cash equivalents, ending the quarter with ¥679.13 million, down from ¥750.59 million at the end of the previous year[25] - As of September 30, 2022, the company's cash and cash equivalents amounted to 679,125,409.23 CNY, a decrease from 791,989,554.14 CNY at the beginning of the year[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,318,664,699.62, reflecting a 16.70% increase from the end of the previous year[5] - The company's total assets reached CNY 7,318,664,699.62, an increase of 16.69% compared to CNY 6,271,432,076.94 in the previous year[21] - Total liabilities increased to CNY 2,386,817,609.95, a rise of 50.59% from CNY 1,585,642,380.84 in the previous year[21] - The company’s total liabilities included new short-term and long-term loans amounting to ¥380,348,251.50 and ¥604,500,000.00 respectively[8] Shareholder Information - The total number of common shareholders at the end of the reporting period was 28,340, with the top 10 shareholders holding a combined 66.39% of shares[10] - Ningbo Kaiming Investment Management Partnership holds 19.22% of shares, amounting to 80,064,000 shares, while Zhejiang Jihe Venture Capital holds 13.04% with 54,324,000 shares[10] - The company continues to maintain a strong shareholder base with significant stakes held by institutional investors[10] - There were no changes in the number of preferred shareholders, indicating stability in this area[11] Research and Development - Research and development expenses for the first nine months of 2022 totaled ¥481,915,519.12, an increase of 31.84% year-over-year[9] - Research and development expenses increased to ¥481.92 million, up 31.8% from ¥365.53 million year-on-year[23] Sales and Inventory - Sales volume of the drug Kaimena increased by 26.54% year-over-year, while Beimeina's sales surged by 797.57%[7] - Total operating costs increased to CNY 1,609,425,586.40, up 17.61% from CNY 1,368,288,679.61 in the previous year[22] - Inventory as of Q3 2022 was CNY 371,966,757.74, an increase of 26.83% from CNY 293,321,689.12 in the previous year[20] Stock Options and Incentives - The total number of stock options exercised and registered during the reporting period was 182,664, with a cumulative total of 930,889 options exercised, representing 53.04% of the total available options[14] - The total number of stock options available for incentive objects was 2,126,464, with 241,489 options exercised during the reporting period, representing 56.14% of the total[14] - The 2018 (second phase) stock option incentive plan saw 930,889 stock options exercised, with 182,664 options exercised in the reporting period[13] - The company adjusted the grant price of the 2021 restricted stock incentive plan from 41.34 CNY/share to 41.09 CNY/share, granting a total of 2,802,100 restricted shares to 238 eligible participants[15] Management and Governance - The company’s management expenses increased by 109.40% to ¥429,057,814.32, largely due to stock incentive expenses[9] - The company’s independent directors approved the adjustments to the incentive plan, ensuring compliance with governance standards[15] - The company has disclosed various important matters in temporary reports, including announcements regarding shareholder pledge releases and extensions[18] Strategic Initiatives - The company has not reported any new product launches or technological developments in this quarter[12] - The company has not disclosed any plans for market expansion or mergers and acquisitions in this report[12] - The company continues to focus on market expansion and new product development as part of its strategic initiatives[18]

Financial Performance - Betta Pharmaceuticals reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[8]. - The company’s net profit for the same period was RMB 300 million, showing a growth of 10% compared to the previous year[8]. - The management has set a revenue target of RMB 2.5 billion for the full year 2022, reflecting a growth rate of 20%[8]. - The company's operating revenue for the reporting period was ¥1,253,336,956.19, representing an increase of 8.50% compared to the same period last year[13]. - The net profit attributable to shareholders was ¥94,717,355.06, a decrease of 55.96% year-on-year[13]. - The net profit after deducting non-recurring gains and losses was ¥60,334,511.27, down 69.45% from the previous year[13]. - The basic earnings per share decreased to ¥0.23, down 55.77% from the previous year[13]. - The weighted average return on net assets was 2.04%, a decrease of 3.02% compared to the previous year[13]. - The company reported a net loss of ¥128 million for the first half of 2022, indicating a loss compared to the previous period[147]. Research and Development - The company has allocated RMB 200 million for R&D in new drug development, emphasizing its commitment to innovation[8]. - The company has established a leading domestic new drug R&D system with research centers in Beijing and Hangzhou, continuously increasing investment in new drug development[26]. - R&D investment for the first half of 2022 was CNY 459.21 million, up 15.27% year-on-year, with R&D expenses of CNY 317.07 million, a 30.65% increase[32]. - The company has a robust pipeline with five drugs in late-stage clinical research or submitted for approval, alongside over 40 ongoing projects[39]. - The company is committed to broadening its R&D pipeline, with ongoing clinical trials for various cancer treatments and other therapeutic areas[36]. Market Expansion and Strategy - Betta Pharmaceuticals is focusing on market expansion in Southeast Asia, targeting a 25% increase in market share in the region by 2023[8]. - The company plans to launch two new oncology drugs by the end of 2022, aiming to expand its product portfolio significantly[8]. - The company aims to leverage the successful promotion experience of Kaimena and Beimina to enhance Beianting's market strategy[24]. - The company is committed to becoming a multinational pharmaceutical enterprise headquartered in China, focusing on independent R&D and strategic cooperation[29]. - The company is actively pursuing strategic partnerships, including a collaboration agreement with EyePoint for EYP-1901[112]. Product Development and Clinical Trials - The BRAIN study demonstrated that Camrelizumab is significantly more effective than whole-brain radiotherapy for patients with EGFR mutations and brain metastases, establishing it as a preferred treatment in China[20]. - The INCREASE study showed that increasing the dose of Camrelizumab for patients with the 21-L858R mutation achieves efficacy comparable to standard doses for the 19-Del mutation patients, highlighting its innovative value[20]. - The EVIDENCE study, a pivotal III phase clinical trial, supports the use of Camrelizumab as adjuvant therapy for early-stage EGFR-sensitive NSCLC patients, with approval granted in June 2021[20]. - The company has initiated a clinical trial for Beimu as adjuvant therapy for ALK-positive NSCLC, with ongoing research showing promising results[22]. - The company has received FDA approval for the clinical trial of BPI-442096, marking a key milestone in its product pipeline[112]. Financial Management and Investments - The company has invested heavily in R&D, with R&D expenses accounting for 43.41%, 39.69%, and 38.32% of revenue over the past three years[39]. - The total investment amount during the reporting period was ¥1,005,932,685.83, a significant increase of 278.22% compared to ¥265,966,874.48 in the same period last year[51]. - The company has a total of ¥537,300,533.20 in financial assets, with a significant portion being trading financial assets valued at ¥50,000,000.00[50]. - The company reported a significant increase in other income to CNY 42,576,373.03, compared to CNY 14,245,475.24 in the first half of 2021[138]. - The company reported a total of ¥2.12 billion in other equity instruments, indicating a stable financial structure[149]. Compliance and Governance - The company has received an A-level rating for information disclosure from the Shenzhen Stock Exchange for three consecutive years, reflecting its commitment to transparency[85]. - The company has established a robust governance structure, with its financial reports approved by the board of directors[152]. - The company has implemented a robust compliance management system, including anti-corruption and anti-fraud measures, to mitigate operational risks[85]. - The company has maintained a profit distribution policy, ensuring that at least 20% of the distributable profits are allocated as cash dividends to shareholders annually[85]. - The company has a comprehensive financial reporting framework in place, adhering to the accounting standards set by the Ministry of Finance[156]. Environmental Responsibility - The company reported no exceedances in pollutant emissions against the established standards for wastewater and air emissions[78]. - The company has implemented pollution prevention facilities that are operational and compliant with environmental standards[80]. - The company has established a waste water online monitoring system at both the Wuzhou Road and Xingzhong Road plants, ensuring daily quality and quantity assessments[83]. - The company has commissioned qualified third-party organizations to conduct regular monitoring of wastewater, waste gas, and noise at its production facilities[83]. - The company emphasizes the importance of social responsibility, aiming to integrate innovation in drug development with community welfare[84]. Employee Relations and Corporate Culture - The company has a 100% labor contract signing rate with employees, ensuring compliance with legal requirements[88]. - Employee compensation includes fixed and variable income, with a focus on competitive salaries and performance bonuses to encourage excellence[88]. - In the first half of 2022, the company improved various employee benefits, enhancing the overall work experience and creating a harmonious work environment[88]. - The company organized multiple cultural and sports events in 2022, strengthening employee recognition of the company culture and enhancing team cohesion[89]. - The company has introduced over 100 senior professionals and management personnel in the first half of the year to strengthen its core team[38].

Financial Performance - The company's revenue for Q1 2022 was ¥584,705,632.04, a decrease of 5.47% compared to ¥618,561,581.32 in the same period last year[3] - Net profit attributable to shareholders was ¥83,678,928.89, down 43.36% from ¥147,745,673.33 year-on-year[3] - The net cash flow from operating activities was ¥29,306,885.70, reflecting a significant decline of 62.21% compared to ¥77,551,312.52 in the previous year[3] - Basic earnings per share decreased to ¥0.20, down 44.44% from ¥0.36 in the same period last year[3] - Total operating revenue decreased to ¥584,705,632.04 from ¥618,561,581.32, representing a decline of approximately 5.5% year-over-year[21] - Net profit for the period was ¥79,272,651.53, down from ¥146,483,729.42, reflecting a decrease of approximately 46% year-over-year[22] - The company recorded a total comprehensive income of ¥52,598,102.57, down from ¥145,422,673.14, reflecting a decrease of about 64% year-over-year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,584,330,493.66, an increase of 4.99% from ¥6,271,432,076.94 at the end of the previous year[3] - The total current assets decreased from CNY 1,653,935,668.95 to CNY 1,521,527,534.15, a decline of approximately 8%[18] - The company's non-current assets increased from CNY 4,617,496,407.99 to CNY 5,062,802,959.51, representing an increase of about 9.6%[19] - The company's total liabilities increased from CNY 1,585,642,380.84 to CNY 1,792,191,334.80, reflecting an increase of about 13%[19] - The company's equity attributable to shareholders rose from CNY 4,560,887,934.57 to CNY 4,671,719,604.98, an increase of approximately 2.4%[20] Cash Flow - The company reported cash and cash equivalents of CNY 683,401,069.14, down from CNY 791,989,554.14, a decrease of about 13.7%[17] - Cash inflow from investment activities was ¥201,579,835.62, down from ¥522,454,394.17, indicating a decline of approximately 61% year-over-year[23] - The total cash inflow from financing activities was 438,021,887.80 CNY, while the cash outflow was 8,265,248.00 CNY, resulting in a net cash flow of 429,756,639.80 CNY[24] - The net increase in cash and cash equivalents was -108,588,485.00 CNY, compared to -515,163,728.92 CNY in the previous period[24] Operational Changes and Investments - The company raised ¥429,756,639.80 from financing activities, a dramatic increase of 21,899.68% compared to a cash outflow of ¥1,971,390.00 in the previous period[5] - The company made new investments in Wuhan Heyuan Biotechnology Co., Ltd. and Zhejiang Shimai Pharmaceutical Co., Ltd., leading to a 138.75% increase in other equity instrument investments to ¥802,919,674.87[5] - The company plans to temporarily use up to RMB 300 million of idle raised funds to supplement working capital, with a usage period not exceeding 12 months[14] - The company plans to invest CNY 30 million in Zhejiang Shimai Pharmaceutical Co., Ltd., acquiring a 1.3453% stake, and will also invest CNY 76 million to acquire an additional 3.4081% stake from Ningbo Kaiming Investment Management Partnership[16] Research and Development - The clinical trial application for BPI-371153, an innovative oral PD-L1 inhibitor, was approved in January 2022, indicating ongoing R&D efforts[12] - The company has successfully commercialized Beanting, which was approved for multiple cancer indications, including metastatic colorectal cancer and advanced NSCLC[12] - Research and development expenses were ¥107,640,306.79, down from ¥118,329,417.69, showing a reduction of about 9% year-over-year[21] Management and Governance - The company’s actual controller holds a total of 23.01% of the shares, ensuring stable governance and control[9] - The company appointed Mr. Cai Wanyu as Senior Vice President to manage the production center and Shengzhou industrial base, effective from January 21, 2022[15] - The company is focused on enhancing its business capabilities to ensure stable production and market promotion of its drugs amid market changes[11]

Financial Performance - The company's operating revenue for 2021 was ¥2,245,855,591.46, representing a 20.08% increase compared to ¥1,870,266,314.97 in 2020[12]. - The net profit attributable to shareholders for 2021 was ¥383,067,840.44, a decrease of 36.83% from ¥606,360,588.51 in 2020[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥345,680,213.55, which is a 3.52% increase from ¥333,928,877.30 in 2020[12]. - The total assets at the end of 2021 were ¥6,271,432,076.94, reflecting a 19.92% increase from ¥5,229,537,607.09 at the end of 2020[12]. - The basic earnings per share for 2021 was ¥0.92, down 38.67% from ¥1.50 in 2020[12]. - The company reported a net cash flow from operating activities of ¥526,630,893.24, a decrease of 18.48% compared to ¥646,022,131.84 in 2020[12]. - In 2021, the company achieved revenue of 2,245.86 million CNY, a year-on-year increase of 20.08%[31]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 345.68 million CNY, up 3.52% year-on-year[31]. Research and Development - The company has established research centers in Beijing and Hangzhou to enhance its drug development capabilities[5]. - The company is focusing on innovation and clinical value-driven development in response to the competitive landscape of the oncology drug market[19]. - The company has established a robust R&D pipeline, with five drugs in late-stage clinical research and over 40 ongoing projects[38]. - The company invested approximately ¥860.59 million in R&D in 2021, representing 38.32% of its operating revenue, a decrease from 39.69% in 2020[62]. - The number of R&D personnel increased by 12.97% from 509 in 2020 to 575 in 2021, with a notable rise in the number of PhD holders by 21.62%[62]. - The company is actively preparing to submit a first-line indication application for Beimu to the FDA, aiming for global market entry[25]. - The company aims to broaden its R&D pipeline with ongoing clinical trials for various drug candidates, including BPI-421286, a KRAS G12C inhibitor, which has completed Phase I trials[60]. Product Portfolio and Market Strategy - The company is focused on expanding its product portfolio, including new drugs like Ensartinib, a next-generation ALK inhibitor[5]. - The annual sales of the star product, Kaimena, have exceeded 1 billion RMB for six consecutive years, with cumulative sales surpassing 10 billion RMB[22]. - Kaimena is the first targeted oral drug for postoperative adjuvant therapy of lung cancer included in the National Medical Insurance Directory, enhancing its market coverage[23]. - The company aims to strengthen its market position through strategic partnerships and potential acquisitions in the pharmaceutical sector[5]. - Beimeina was approved for market launch at the end of 2020, and Beianting was approved at the end of 2021, expanding the company's product portfolio[22]. - The company plans to leverage its successful experience with Kaimena to enhance the commercialization strategy for Beimu and Beianting[30]. - The company is actively pursuing mergers and acquisitions to enhance its portfolio and market position[192]. Corporate Governance and Compliance - The company has established a robust internal control system and governance structure to protect investor rights, particularly those of minority shareholders[95]. - The board of directors consists of 11 members, including 4 independent directors, ensuring compliance with legal and regulatory requirements[95]. - The company has implemented a comprehensive internal audit system to oversee financial reporting and internal controls, enhancing transparency and accountability[96]. - The company has maintained compliance with relevant laws and regulations regarding shareholder meetings, ensuring equal treatment of all shareholders[95]. - The company has conducted a self-assessment of its governance practices, confirming alignment with regulatory standards[96]. - The company emphasizes social responsibility, participating in environmental protection and public welfare initiatives[96]. - The company has established a clear information disclosure policy, ensuring timely and accurate communication of financial and operational information[96]. Environmental Responsibility - The company reported a total wastewater discharge of 2.345 tons of COD, which is below the approved discharge limit of 12.363 tons[147]. - The company maintained compliance with the wastewater discharge standards, with no exceedances reported for key pollutants such as BOD and SS[147]. - The company’s air emissions for dust were measured at 1.30 mg/m3, adhering to the atmospheric pollutant discharge standards[148]. - The company has implemented measures to ensure that all reported emissions and discharges are within the specified environmental standards, with no exceedances noted[147][148]. - The company operates two production facilities with a wastewater treatment capacity of 200 tons per day at both sites, ensuring compliance with environmental standards without any exceedance incidents reported during the reporting period[150]. - The company has established an emergency response plan for environmental incidents, with the Wuzhou Road facility's plan filed in March 2020 and the Xiongzhong Road facility's plan refiled in November 2021[151]. - The company has successfully integrated environmental protection measures into its operational practices, with no administrative penalties for environmental issues reported during the period[151]. Employee Engagement and Welfare - The company has established a comprehensive employee welfare program, including competitive vacation policies to ensure work-life balance[127]. - The company provides competitive salaries with a fixed income adjusted according to market conditions and a variable income that includes bonuses and performance-related pay[157]. - Over 30% of employees are covered by the company's stock incentive plan, promoting shared growth and benefits[157]. - The company has implemented a five-year stock incentive plan in 2021 to promote employee growth alongside the company[127]. - The company conducted 434 offline training sessions and 142 online courses, totaling 22,546.22 training hours, with an average of 13.13 hours per employee[128]. - The company has a total of 36 internal trainers to develop and optimize professional training courses[128]. - The company has strengthened its corporate culture through various employee engagement activities, enhancing employee loyalty and morale[159]. Strategic Partnerships and Collaborations - Strategic collaborations have been formed with companies like Agenus and Merus, introducing several new drug candidates, enhancing the existing R&D pipeline[39]. - The company aims to strengthen strategic partnerships to introduce new projects and expand its market presence in cancer treatment[85]. - The company is actively responding to new provincial policies to maintain the stability of Kaimena's pricing and ensure patient access to medication[44]. - The company has established significant influence in the healthcare sector through initiatives like the "Shanghai Roundtable on Health Policy" and the "China Health Industry Innovation Platform" (CHIP)[107]. Future Outlook - The company emphasizes the importance of risk awareness regarding market competition and new drug development in its future outlook[4]. - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to 1.8 billion RMB[113]. - The company plans to invest 100 million RMB in digital transformation initiatives to enhance operational efficiency[113]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share within the next two years[113]. - The company will focus on new drug research and development in the oncology field, with ongoing projects including BPI-16350, MCLA-129, and the NDA submission for ensartinib in the US[84].

Financial Performance - The company's revenue for Q3 2021 was ¥569,266,996.07, representing a 2.42% increase year-over-year, while the year-to-date revenue reached ¥1,724,419,673.98, up 14.37% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2021 was ¥131,770,354.58, a decrease of 64.39% year-over-year, with a year-to-date net profit of ¥346,853,778.64, down 32.50% compared to the previous year[5] - The company reported a basic earnings per share of ¥0.32 for Q3 2021, down 65.22% year-over-year, and a diluted earnings per share of ¥0.31, down 65.93%[5] - Total operating revenue for the third quarter reached CNY 1,724,419,673.98, an increase of 14.4% compared to CNY 1,507,722,516.09 in the same period last year[27] - Net profit attributable to the parent company was CNY 346,853,778.64, down 32.5% from CNY 513,827,655.16 in the previous year[28] - Operating profit decreased to CNY 383,479,137.34, a decline of 37.4% compared to CNY 613,155,872.02 in the same quarter last year[27] - Total comprehensive income for the period was CNY 419,244,792.19, compared to CNY 504,864,053.52 in the same quarter last year[28] - Basic earnings per share decreased to CNY 0.84 from CNY 1.28 in the previous year[28] Research and Development - Research and development expenses for the first nine months of 2021 totaled ¥60,217,570, accounting for 34.92% of total revenue, reflecting a 37.02% increase year-over-year[7] - Research and development expenses increased to CNY 365,531,682.04, representing a 37.0% rise from CNY 266,779,354.07 in the prior year[27] - The company has received clinical trial approval for BPI-23314 tablets, indicating ongoing investment in new product development[25] Cash Flow and Assets - The company's cash flow from operating activities for the year-to-date period was ¥460,457,758.90, showing a decrease of 6.09% compared to the previous year[5] - Cash flow from operating activities generated CNY 460,457,758.90, slightly down from CNY 490,329,482.04 in the previous year[30] - Total assets at the end of Q3 2021 were ¥5,681,035,768.82, an increase of 8.63% from the end of the previous year[5] - The company's cash and cash equivalents decreased by 44.23% to ¥750,593,035.82 compared to the end of the previous year[8] - The company's cash and cash equivalents decreased to CNY 750,593,035.82 from CNY 1,345,944,580.99, a decline of about 44.2%[24] - Accounts receivable increased by 163.20% to ¥138,476,016.95, attributed to increased sales of new drugs[8] - Inventory levels rose to CNY 279,213,920.81, up from CNY 188,593,932.18, indicating an increase of around 48.0%[24] - Total liabilities reached CNY 1,158,889,108.06, compared to CNY 1,085,342,634.36 at the end of 2020, reflecting an increase of about 6.8%[26] - The company's equity attributable to shareholders increased to CNY 4,522,508,063.49 from CNY 4,140,781,110.43, representing a growth of approximately 9.2%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,100, with the top 10 shareholders holding a combined 66.54% of shares[10] - Ningbo Kaiming Investment Management Partnership holds 19.28% of shares, amounting to 80,064,000 shares, and has pledged 37,810,000 shares[10] - Zhejiang Jihe Venture Capital holds 13.08% of shares, totaling 54,324,000 shares[10] - The total number of shares held by the top 10 shareholders is 277,000,000 shares[11] - The actual controller holds a total of 23.02% of shares through various investment partnerships[11] - The number of shares held by the top 10 shareholders participating in margin trading is 77,284,000 shares[11] Stock Options and Incentives - The company has implemented stock option incentive plans, with 231 participants exercising options at a price of 34.85 RMB per share, involving 2,142,190 options[15] - The total share capital increased from 41,498,520 shares to 41,530,510 shares due to the exercise of stock options[15] - The company has a total of 1,416,665 restricted shares at the end of the reporting period, with 12,750 shares released from restrictions[13] - The total number of restricted shares to be granted under the 2021 incentive plan has been adjusted from 15.55 million shares to 15.53 million shares, with the number of incentive recipients reduced from 468 to 466[19] - The initial grant of restricted shares has been adjusted from 12.7479 million shares to 12.7279 million shares, with a reserved portion of 2.8021 million shares, accounting for 18.04% of the total[19] - The cumulative number of stock options exercised and registered as of the report date is 2.14219 million shares, representing 96.25% of the total available options[16] Other Financial Information - The company reported a significant increase in other receivables by 472.12% to ¥38,955,380.86, mainly due to increased employee stock option tax receivables[8] - The company reported a net cash outflow from investing activities of CNY -899,198,899.41, compared to CNY -446,143,499.85 in the previous year[30] - The company’s financial statements for the third quarter of 2021 were unaudited[36]

Financial Performance - The company's operating revenue for the reporting period was ¥1,155,152,677.91, representing a 21.35% increase compared to ¥951,884,867.49 in the same period last year[13]. - Net profit attributable to shareholders was ¥215,083,424.06, a 49.57% increase from ¥143,798,418.73 year-over-year[13]. - The net profit after deducting non-recurring gains and losses was ¥197,517,963.56, up 39.85% from ¥141,238,347.17 in the previous year[13]. - The net cash flow from operating activities decreased by 35.25% to ¥228,977,955.65 from ¥353,608,692.17 in the same period last year[13]. - The total assets at the end of the reporting period were ¥5,596,696,415.37, reflecting a 7.02% increase from ¥5,229,537,607.09 at the end of the previous year[13]. - The net assets attributable to shareholders increased by 5.81% to ¥4,381,261,315.95 from ¥4,140,781,110.43 at the end of the previous year[13]. - Total revenue for the reporting period reached approximately 1.155 billion CNY, reflecting a year-on-year increase of 21.35%[50]. - The cost of sales increased by 24.38% year-on-year, amounting to approximately 84.29 million CNY[50]. - R&D expenses rose to approximately 398.38 million CNY, marking a 6.98% increase compared to the previous year[51]. - The gross margin for drug sales was reported at 94.06%, with a year-on-year increase in sales revenue of 22.79%[52]. Research and Development - R&D investment reached 398 million CNY, accounting for 34.49% of total revenue, supporting a robust pipeline of innovative drugs[28]. - The company has established a comprehensive drug development platform, integrating drug discovery, development, production, and commercialization[24]. - The company submitted 7 IND applications and 2 NDA applications during the reporting period, showcasing its commitment to advancing its drug development pipeline[28]. - The company is actively evaluating and adjusting its research projects based on progress and regulatory requirements, ensuring compliance with disclosure obligations[44]. - The company has multiple ongoing clinical trials for various drug candidates, including those targeting ERK1/2 and FGFR1/2/3, reflecting its strategic focus on innovative cancer therapies[43]. Market Position and Strategy - The company aims to address unmet medical needs in lung cancer treatment through its innovative drug development strategy[20]. - The company is focusing on lung cancer treatment, with a comprehensive strategy that includes various targeted therapies and combination treatments, aiming to meet the unmet clinical needs of lung cancer patients[45]. - The company plans to enhance its market positioning for its products and strengthen patient education initiatives[72]. - The company is actively adapting to changes in market access policies to ensure continuous medication availability for patients[30]. - The company has made significant progress in strategic collaborations, with multiple projects receiving clinical trial approvals, including MCLA-129 and BPI-D0316[32]. Environmental Compliance - The company reported a total wastewater discharge of 0.801 tons of COD, with a concentration of 36.4 mg/L, adhering to the Grade 3 discharge standard[89]. - The company achieved a total nitrogen discharge of 0.098 tons, with a concentration of 12 mg/L, compliant with the relevant discharge standards[89]. - The company has implemented a comprehensive pollution prevention facility at both sites, ensuring proper treatment of wastewater before discharge[92]. - The company has established a robust monitoring system for emissions, with all reported values within the regulatory limits[91]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[88]. Share Capital and Stock Options - The total share capital increased from 413,162,913 shares at the beginning of the period to 414,985,201 shares at the end of the period[12]. - The second phase of the stock option incentive plan had 182.2288 thousand options exercised at a price of 34.85 yuan per option, increasing the total share capital from 413,162.9131 thousand shares to 414,985.2010 thousand shares[85]. - The company has been actively involved in stock option incentive plans, with the latest plan resulting in an increase of registered capital by CNY 182,228.80[164]. - The number of restricted shares decreased by 10,001,246, while unrestricted shares increased by 11,823,534, resulting from the lifting of restrictions on shares issued to specific investors[118]. - As of June 30, 2021, a total of 1,822,288 shares were exercised under the stock option incentive plan, including 280,500 shares by directors and senior management[117]. Corporate Governance - The company held its first extraordinary general meeting of shareholders on January 22, 2021, with a participation rate of 55.73%[80]. - The annual general meeting for 2020 took place on April 15, 2021, with a participation rate of 57.37%[80]. - The company has not reported any significant changes in the feasibility of the committed investment projects[65]. - The company has not engaged in any derivative investments during the reporting period[69]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[135]. Financial Position - The total liabilities reached ¥1,214,785,525.54, up from ¥1,085,342,634.36, indicating an increase of approximately 11.9%[139]. - Shareholders' equity totaled ¥4,381,910,889.83, compared to ¥4,144,194,972.73, reflecting an increase of about 5.7%[140]. - The company reported a significant increase in other receivables, which rose to ¥672,978,782.76 from ¥543,387,489.27, a growth of approximately 23.8%[141]. - The company's total assets reached CNY 5,418,004,752.61 as of June 30, 2021, compared to CNY 5,103,856,075.89 at the end of 2020, reflecting a growth of 6.2%[144]. - The company's total equity attributable to shareholders at the end of the first half of 2021 was ¥4,381,910,889.83, compared to ¥4,144,194,972.73 at the end of the previous year[156].

Financial Performance - Total revenue for Q1 2021 was ¥618,561,581.32, a decrease of 4.41% compared to ¥647,078,509.17 in the same period last year[4] - Net profit attributable to shareholders was ¥147,745,673.33, an increase of 13.24% from ¥130,473,244.06 year-on-year[4] - Net profit excluding non-recurring gains and losses was ¥140,370,122.42, up 7.32% from ¥130,790,505.64 in the previous year[4] - Basic earnings per share increased to ¥0.36, a rise of 9.09% from ¥0.33 in the previous year[4] - The total comprehensive income for the first quarter was CNY 169,161,625.56, an increase from CNY 155,969,994.26 in the previous period, representing an increase of approximately 8.3%[44] - Net profit for Q1 2021 was ¥146.48 million, up 13.3% from ¥129.27 million in the same period last year[40] Cash Flow and Assets - Net cash flow from operating activities was ¥77,551,312.52, down 72.74% from ¥284,445,194.90 in the same period last year[4] - Cash inflow from operating activities totaled CNY 613,994,005.30, compared to CNY 607,333,461.77 in the previous period, showing a slight increase[45] - The net cash flow from operating activities was CNY 77,551,312.52, down from CNY 284,445,194.90 in the previous period, indicating a decrease of approximately 72.7%[46] - The ending cash and cash equivalents balance was CNY 830,780,852.07, up from CNY 674,110,141.01 in the previous period[47] - The company reported a net decrease in cash and cash equivalents of -CNY 515,163,728.92, compared to an increase of CNY 152,812,633.38 in the previous period[46] - Cash and cash equivalents decreased by 38.28% due to the transfer of bank wealth management products to other current assets[11] - The company has 830,780,852.07 in cash as of March 31, 2021, down from 1,345,944,580.99 on December 31, 2020[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,175[7] - The largest shareholder, Ningbo Kaiming Investment Management Partnership, held 19.38% of the shares[7] Research and Development - R&D expenses rose by 31.98% compared to the same period last year, reflecting ongoing investment in new drug development[11] - The company plans to continue focusing on R&D and market expansion strategies to drive future growth[39] - The company submitted IND applications for three candidate drugs (MCLA-129, BPI-421286, and Batilizumab injection) and one NDA application for BPI-D0316 during the reporting period[16] Strategic Initiatives - The company maintained a strong focus on its differentiated competitive strategy for its product, Kai Mei Na, which contributed to sales growth[12] - The company is focusing on risk management strategies to address market competition, new drug development, and potential loss of core technical personnel[18][20][22] - The company plans to strengthen its market positioning for Kaimena with a differentiated competition strategy and enhance patient education through new media[19] - The company has established strategic partnerships with over 10 domestic and international companies, enhancing its product pipeline through licensing and strategic investments[13] Financial Position - Total assets at the end of the reporting period were ¥5,348,236,146.44, an increase of 2.27% from ¥5,229,537,607.09 at the end of the previous year[4] - Net assets attributable to shareholders increased to ¥4,290,449,935.91, up 3.61% from ¥4,140,781,110.43 at the end of the previous year[4] - The total liabilities decreased to CNY 453,893,705.73 from CNY 489,989,827.62, representing a reduction of about 7.4%[38] - The company's equity increased to CNY 4,797,587,475.08 from CNY 4,613,866,248.27, indicating a growth of approximately 4.0%[38] Operational Efficiency - The company effectively controlled expenses, contributing to the increase in net profit attributable to shareholders[12] - Total operating costs decreased by 7.4% to ¥454.70 million from ¥491.08 million year-over-year[39] - Sales expenses decreased by 8.9% to ¥235.27 million from ¥258.31 million year-over-year[39] - The company experienced a tax expense reduction of 8.5%, down to ¥25.96 million from ¥28.41 million in the previous year[40]